Luke Jonathan Alvey

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Galapagos Nv, Abbvie S.a.r.l., Les Laboratoires Servier. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Luke Jonathan Alvey. Retrieved from https://idiyas.com/inventor/luke-jonathan-alvey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 3)

% Patents Active = 84.2

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 9.2

ph-index = 4

Forward Citations = 31(Granted Patents)

Location History:

Versailes, FR (2018)
Versailles, FR (2015 - 2022)
Romainville, FR (2018 - 2024)

Company Filing History:

Les Laboratoires Servier

patents

4. 1 out of 53

Les Laboratories Servier

patents

5. 1 out of 2

Onco3r Therapeutics Bv

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

ADAMTS Inhibitors

Inflammatory Disorders

Cystic Fibrosis

Benzamide Compounds

Dihydropyrimidinoisoquinolinones

Pyrazolo Compounds

Pharmaceutical Compositions

Osteoarthritis Treatments

N-sulfonylated Compounds

Imidazolidine Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12391679 - Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases (2025-08-19),

2. 12065443 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2024-08-20),

3. 11718588 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2023-08-08),

4. 11339166 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2022-05-24),

5. 11220499 - Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2022-01-11),

6. 10941117 - 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2021-03-09),

7. 10829478 - 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis (2020-11-10),

8. 10647717 - N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2020-05-12),

9. 10550100 - 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis (2020-02-04),

10. 10487060 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2019-11-26),

11. 10259810 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2019-04-16),

12. 10130622 - Compounds for treatment of cystic fibrosis (2018-11-20),

13. 10047083 - Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2018-08-14),

14. 9926281 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2018-03-27),

15. 9890158 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2018-02-13),

Title: The Inventive Journey of Luke Jonathan Alvey

Introduction:

Luke Jonathan Alvey, a talented inventor based in Versailles, FR, has made significant contributions to the field of pharmaceuticals with a total of 17 patents under his belt. His innovative work focuses on developing compounds for the treatment of various inflammatory conditions and diseases involving cartilage and bone degradation.

Latest Patents:

Alvey's recent patents include groundbreaking inventions such as "5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis." These compounds inhibit ADAMTS and offer promising methods for the prophylaxis and treatment of inflammatory conditions. Additionally, his work on compounds and pharmaceutical compositions for the treatment of various diseases highlights his dedication to improving healthcare outcomes.

Career Highlights:

Throughout his career, Alvey has showcased his expertise while working at renowned companies such as Galapagos NV and AbbVie S.ár.l. His strategic approach to innovation and drug development has positioned him as a key player in the pharmaceutical industry, driving forward advancements in treating complex diseases.

Collaborations:

Alvey has collaborated with esteemed professionals in the field, including Romain Luc Marie Gosmini and Gregory John Robert Newsome. These collaborations have fostered a dynamic environment for idea exchange and accelerated the development of novel compounds for various medical conditions.

Conclusion:

Luke Jonathan Alvey's inventive spirit and commitment to developing effective treatments for challenging diseases have solidified his reputation as a prolific inventor in the pharmaceutical sector. His patents stand as a testament to his innovative thinking and dedication to improving global healthcare.

Profile summary based on public USPTO records.